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Abstract: Fungal keratitis is one of the major causes of ophthalmic mycosis and is difficult to 
treat. The range of common antifungal agents available for fungal keratitis remains inadequate 
and is generally associated with poor clinical outcomes. Voriconazole is a new generation triazole 
antifungal agent. Only marketed in systemic formulation and, with broad-spectrum activity 
and high intraocular penetration, voriconazole has demonstrated effectiveness against fungal 
keratitis. Systemic voriconazole, however, is not without side effects and is costly. Voriconazole 
eye drops have been prepared extemporaneously and used for the treatment of ophthalmic 
fungal keratitis. The current article sought to review the literature for evidence related to the 
effectiveness and safety of topical voriconazole and its corneal penetration into the aqueous 
humor of the eye. The voriconazole eye drops used are typically of 1% concentration, well 
tolerated by the eye, and are stable. Despite existing evidence to suggest that the eye drops are 
effective in the treatment of fungal keratitis, more studies are needed, especially in relation to 
using the eye drops as first-line and stand-alone treatment, preparation of higher concentrations, 
and optimal dosing frequency.
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Introduction
Corneal disease is second only to cataracts as the most common cause of blindness 
worldwide, resulting in more than 1.5 million new cases of vision loss annually.1 
As a consequence of attention being directed towards the management of cataracts, 
especially in developing countries, strategies for the management of traditional 
infections that cause blindness have been neglected.2
Ophthalmic mycosis is emerging as a major cause of vision loss and morbidity, 
and can be life-threatening.3,4 Fungal keratitis is one of the major causes of ophthalmic 
mycosis,5 accounting for more than 50% of proven ophthalmic mycoses in some 
countries.6 Fungal keratitis is usually characterized by a corneal epithelial defect and 
inflammation of the corneal stroma. If untreated, fungal keratitis can lead to corneal 
scarring and vision loss.1
Fungal keratitis
The first description of fungal keratitis was in the late 1870s.7 Fungal keratitis is most 
common in tropical regions and developing countries, where it constitutes over 50% of 
keratitis.8 In South India, about 44% of corneal ulcers are caused by fungi. Although 
lower, the prevalence of fungal keratitis is still relatively high in other countries, being 
17% in Nepal, 36% in Bangladesh, 38% in Ghana, and 35% in south Florida in the US. Clinical Ophthalmology 2010:4 392
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In China, the incidence has been increasing in the past decade.9 
By contrast, fungal keratitis generally accounts for only 1%–5% 
of the keratitis treated in developed countries and temperate 
regions, such as Britain and the northern US.9,10 This also 
applies to Australia, where the incidence of fungal keratitis at 
the Royal Victorian Eye and Ear Hospital (RVEEH) in Mel-
bourne was reported at 5%. The RVEEH is a tertiary referral 
eye hospital responsible for the care of most serious corneal 
infections in a population of about five million across Victoria, 
southern New South Wales, and Tasmania.10
Etiology
Filamentous fungi were long considered as a major cause 
of fungal keratitis.11,12 Ophthalmic infections from these 
fungi are most commonly associated with agricultural and 
outdoor activities.13,14 Of the filamentous fungi, infections 
from Fusarium and Aspergillus species are the most common. 
While Fusarium species are particularly prevalent in crop 
plants,15 Aspergillus species are found in decaying vegetation 
and soil. Aspergillus is a contaminant in hospital air and has 
been involved in recent outbreaks of ocular infections in 
several hospitals.16,17 Keratitis caused by these filamentous 
fungi may involve any part of the cornea.18,19 Other less 
common keratitis-causative filamentous fungi include 
Paecilomyces and Acremonium species.20 Paecilomyces 
species have been shown to be resistant to most common 
sterilising techniques, including those applied during surgical 
procedures.21,22 Acremonium species can be isolated from 
a variety of common sources, and can be associated with 
severe eye infections.23,24
Dematiaceous fungi such as Curvularia, Bipolaris, 
and Exserohilum species have also been reported to cause 
fungal keratitis. After Aspergillus and Fusarium species, 
Curvularia and Bipolaris species are the third most common 
keratitis-causative fungi worldwide.20 Curvularia, Bipolaris, 
and Exserohilum species usually cause persistent, but 
low-grade ulcerations near the epithelial part of the cornea. 
These ulcerations, if not appropriately treated or if associated 
with topical steroid use, can develop into resilient infections 
involving the deeper layers of cornea.25–27 Scedosporium and 
Lecytophora species are also dematiaceous fungi that are 
known to result in very severe keratitis infections that often 
do not respond to medical therapies.25,28
Whilst filamentous and dematiaceous fungi are the 
common causes of fungal keratitis at a global level, yeasts are 
the major cause of fungal keratitis in developed countries.8 
Yeasts are infrequent in tropical countries, characterized by 
major agricultural presence, which is associated with higher 
prevalence of other types of fungal keratitis, such as the 
filamentous fungi.20 Yeast infections have no geographical 
dominance and are most commonly caused by Candida 
species, especially Candida albicans.8,10,20 Candida keratitis 
predominantly occurs in the stromal layer of the cornea. It is 
associated with epithelial defect and distinct infiltration, and 
is slow in development.18 Cryptococcus species are another 
type of yeast that causes fungal keratitis, but less commonly 
than Candida species.20
Fungal keratitis can also be caused by zygomycetes fungi 
such as Rhizopus and Mucorales species,4,29,30 and other 
fungi such as Cladosporium, Cylindrocarpon, Penicillium, 
and Chrysonilia species.6,14,31–33 Keratitis due to these fungi, 
however, is very low in occurrence.
The incidence of different types of fungal keratitis in 
various areas and countries is shown in Table 1.
Risk factors
The general predisposing factors for fungal keratitis 
include ocular trauma, prolonged use of topical or systemic 
immunosuppressants, pre-existing corneal surface disease, 
underlying systemic disease (eg, diabetes mellitus), and 
contact lens wear.10,20,35
The significance of these factors, however, varies 
according to geographical area. For instance, in Melbourne, 
ocular trauma, chronic steroid use, and ocular surface disease 
were the most common risk factors,10 whilst the common 
risk factors in Philadelphia were ocular surface disease, 
contact lens wear, and topical steroids.33 In the southern US, 
however, trauma was generally identified as the major risk 
factor for fungal keratitis. A similar trend was also observed 
in Singapore and Bangladesh.36,37 In contrast, in the northern 
US, ocular trauma was reported as only a secondary risk 
factor for fungal keratitis.9
The type of predisposing risk factors relates to the type 
of causative fungi. For example, keratitis associated with 
ocular trauma is commonly caused by Aspergillus, Fusarium, 
and Curvularia species.14 The use of lawn trimmers was 
found to be associated with Fusarium and Curvularia 
keratitis,14,38 while the use of topical steroids was linked to 
Candida, Aspergillus, Acremonium, and Curvularia keratitis. 
Underlying chronic diseases were frequently related to 
keratitis caused by Fusarium and Candida species.14 Candida 
keratitis is common where traumatic keratitis is infrequent.20 
Previous corneal ulceration resulting, for example, from 
previous keratitis or contact lens-related trauma, is a 
particular risk factor for Candida keratitis.18 Trauma by plant 
material, contaminated water, or immune suppression is a risk Clinical Ophthalmology 2010:4 393
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factor for keratitis caused by Scedosporium apiospermum.20 
Keratitis caused by Paecilomyces species has been reported 
following surgical procedures.21,39
Treatment
The ultimate goal in the treatment of fungal keratitis is 
to conserve vision. This requires timely diagnosis of the 
infection and administration of the appropriate antifungal 
therapy.40 Patient with fungal keratitis can be treated 
with either medical or surgical therapy. Whilst surgical 
procedures are more effective in patients with acute corneal 
perforation, antifungal agents are still the major therapeutic 
option in fungal keratitis,41 whereby success depends on 
the agent’s ability to penetrate into the aqueous humor 
and achieve therapeutic levels. Currently, the range of 
antifungal therapies available for fungal keratitis remains 
inadequate.9,42 The antifungal agents that can be used in 
fungal keratitis are broadly divided into three main groups: 
polyenes (amphotericin B, natamycin, and nystatin), 
azoles (ketoconazole, miconazole, econazole, fluconazole, 
itraconazole, voriconazole, and posaconazole), allylamine 
(terbinafine) and echinocandins (caspofungin).
Amphotericin B has poor ocular penetration after 
intravenous (IV) administration and, hence, the administration 
of higher doses may be required to ensure adequate 
concentration of amphotericin B in the eye;20,43 however, 
IV administration of high-dose amphotericin B is known to 
cause severe renal toxicity, which can occur in up to 80% of 
patients.20,43 To minimize renal toxicity, low-dose amphoteri-
cin B is often used, which in many cases, results in suboptimal 
doses,44 especially when taking its poor ocular penetration 
into consideration. Amphotericin B eye drops are manufac-
tured extemporaneously by hospital pharmacy departments. 
The most commonly prescribed concentration of the eye 
drops for fungal keratitis is 0.15%.10,20 Topical amphotericin 
B penetrates well into the stroma and can achieve sufficient 
concentrations against susceptible fungi;20 however, its pen-
etration through the cornea with intact epithelium is poor. 
Whilst amphotericin B is active against Aspergillus and 
Candida keratitis, it has no activity against keratitis caused 
by Fusarium species.9,45
Natamycin is the only commercially available topical 
antifungal preparation approved by the Food and Drug 
Adminstration for ophthalmic use.28,46 It is insoluble in water 
Table 1 Studies of the incidence of types of fungal keratitis8,10,13,20,34
Place Number of patients Study duration Principal pathogen (%)
Melbourne, Australia 56 18 months Candida albicans (37), Aspergillus fumigatus (17), 
Fusarium spp. (14)
Madurai, India 434 3 months Fusarium spp. (47), Aspergillus spp. (16)
London, UK 65 13 years Candida albicans (35), Candida parapsilosis (15), 
Fusarium solani (11), Aspergillus fumigatus (9)
Hyderabad, India 1352 10 years Fusarium spp. (37), Aspergillus spp. (31)
Paraguay 45 1 year Fusarium spp. (42), Aspergillus spp. (21)
Sri Lanka 66 2 years Aspergillus spp. (25)
Florida, US 125 10 years Fusarium spp. (68), Candida spp. (14),  
Curvularia spp. (9)
Bangladesh 142 11 months Aspergillus spp. (37), Fusarium spp. (20),  
Curvularia spp. (18)
Ghana 199 N/A Fusarium spp. (52), Aspergillus spp. (15),  
Lecytophora theobromae (9)
New Delhi, India 211 5 years Aspergillus spp. (40), Fusarium spp. (14),  
Alternaria spp. (10)
Singapore 29 5 years Fusarium spp. (52), Aspergillus flavus (17)
Philadelphia, US 24 9 years Candida albicans (46), Fusarium spp. (25)
Houston, US 32 30 years Curvularia senegalensis (30), Curvularia  
lunata (25)
Qingdao, China 108 4 years Fusarium spp. (65), Aspergillus spp. (14),  
Candida spp. (9)
Nepal 405 2 years Aspergillus spp. (47), Candida spp. (13),  
Fusarium spp. (12)
Abbreviations: spp., species; N/A, not available.Clinical Ophthalmology 2010:4 394
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and is stable in 5% suspension.20 Natamycin is the standard of 
care in many countries, especially developed countries,9,10,20 
and is initially administered as one drop every one or two 
hours.47 It adheres well to the cornea surface, is well tolerated, 
has good activity against Candida, Aspergillus, and Fusarium, 
and is routinely used for keratitis caused by filamentous 
fungi.9,20 This antifungal, however, has poor penetration 
into deeper structures of the eye and, hence, is generally 
effective against superficial infections that are not severe.9,48 
In addition, only about 2% of the drug is bioavailable after 
topical application.49 The usefulness of topical natamycin is 
further complicated by the fact that it settles out on the cornea 
upon instillation and degrades easily.28
Nystatin is another polyene that can be used topically 
as a suspension in fungal keratitis. However, nystatin is 
rarely used clinically due to the availability of more potent 
polyene agents.50
Ketoconazole has a broad spectrum of activity, including 
against Aspergillus, Candida, and Fusarium species.28 
It is available orally and, although it has demonstrated 
good tissue distribution after administration,46 it has not 
been used for fungal keratitis. Long-term administration 
of high-dose ketoconazole may result in impotence, 
gynecomastia, or alopecia, which is problematic considering 
the long-term nature of keratitis therapy.51 Topical 1% eye 
drops and suspension formulations of ketoconazole have been 
extemporaneously prepared and used for fungal keratitis. 
These have been reported to inhibit the progression of corneal 
fungal infections and were not associated with significant 
corneal toxicity. 52,53
Miconazole has been used in patients with S. apiospermum 
orbital infections.20 It has a broad spectrum of activity, 
including against Aspergillus, Candida, and Scedosporium 
species.20 Systemic miconazole, however, is associated 
with significant toxicity and has resulted in undetectable 
concentrations in the cornea.20,54 Topical application of 
extemporaneously prepared 1% miconazole eye drops 
achieved high concentrations in the ocular tissues.54 The 
eye drops are generally well tolerated and are used as 
second-line therapy in fungal keratitis that is unresponsive 
to natamycin.54
Econazole has a broad spectrum of activity against 
filamentous fungi, and is effective against Fusarium 
keratitis.55 Topical application of 2% econazole appears to 
be as effective as 5% natamycin in fungal keratitis,56 but has 
been associated with ocular irritation.55
Oral and IV fluconazole are very safe, and penetrate very 
well into the corneal tissue.20,57,58 Whilst oral fluconazole 
is a commonly used agent for the treatment of fungal 
keratitis,10 topical application of 0.2% fluconazole solution 
is as effective as systemic fluconazole. Fluconazole, when 
applied topically, penetrates well into the cornea, is safe, 
and has been used successfully against fungal keratitis.59–61 
A major limitation associated with fluconazole, however, 
is its narrow spectrum of antifungal activity. Fluconazole 
is inactive against Aspergillus and Fusarium species;62 
although active against Candida species, it is less active 
against Candida glabrata and Candida krusei than against 
C. albicans.46
Although itraconazole is commonly associated with 
gastrointestinal side effects, it is considered relatively safe.63 
It has activity against Candida and Aspergillus species; 
however, is rarely used for the treatment of fungal keratitis.28 
Itraconazole is inactive against Fusarium species10,28 but, 
more importantly, it has poor penetration into the cornea 
after systemic administration.64 Experimental use of topical 
itraconazole (1% solution) has been reported, but appears to 
demonstrate insufficient corneal penetration.65
Voriconazole, a more recent azole antifungal, is 
available commercially for systemic administration in 
the form of oral and IV formulations. It has an excellent 
broad spectrum of antifungal activity and is active against 
species that are known to be resistant to the other antifungal 
agents commonly used in fungal keratitis.28 Voriconazole is 
increasingly being used, orally in particular, against fungal 
keratitis. Oral voriconazole is highly bioavailable (96%) and 
has demonstrated good penetration into the different parts 
of the eye,66,67 with sufficient concentrations achieved to 
cover a wide range of keratitis-causative fungi.28 However, 
oral voriconazole can be associated with side effects as 
well as significant drug interactions.68 Topical voriconazole 
eye drops, manufactured extemporaneously and used in an 
off-label manner, have also been prescribed for the treatment 
of keratitis, with promising results.69 With topical administra-
tion, voriconazole demonstrated good penetration through 
the cornea into the aqueous humour,69 without compromising 
intraocular safety.70
Posaconazole has an excellent broad spectrum of 
activity and is as active as voriconazole, with added activity 
against zygomycetes.71 It is safe, with mild gastrointestinal 
side effects being the most common adverse events.72 
Posaconazole was only recently introduced worldwide and, 
as such, studies on its ocular penetration are lacking. In 
a number of recent case reports involving the use of oral 
posaconazole alone as salvage therapy, or in combination 
with topical posaconazole, this antifungal agent demonstrated Clinical Ophthalmology 2010:4 395
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success against fungal keratitis.73,74 The formulation used for 
the topical posaconazole was the same formulation used for 
the oral suspension (10 mg/0.1 mL).28
Terbinafine is fungicidal against many molds, but only a 
few types of yeast.75 Despite its activity, its clinical efficacy 
and use are limited by its pharmacokinetic characteristics 
after the systemic administration.76,77 When used as 0.25% 
eye drops, however, it is as effective against filamentous 
mycotic keratitis as 5% natamycin, especially in cases with 
smaller and shallower ulcers.78 The eye drops are safe, but 
required longer durations of treatment when compared with 
other common topical therapies.78
Caspofungin has significantly less systemic toxicity 
than azoles. Intravenously administered caspofungin does 
not penetrate well into the eye and, hence, it is not used for 
fungal keratitis.79 Nonetheless, in one recent case report, 
when administered topically (0.5%) as adjunctive therapy, 
caspofungin demonstrated clinical success against fungal 
keratitis.60 Caspofungin is safe,79 but lacks activity against 
Fusarium species.9,80
Of the aforementioned antifungal agents, amphotericin B, 
natamycin, fluconazole, and miconazole have been used rou-
tinely to treat fungal keratitis for quite some time; however, 
poor corneal penetration after topical administration, poor 
ocular penetration after systemic administration, limited 
spectra of antifungal activity, and/or limited clinical success 
associated with these agents are major limitations and have 
rendered these therapies challenging and inadequate for fun-
gal keratitis. The limited clinical success is particularly true 
with the topical use of these agents, as they often require co-
administration of an additional systemic antifungal agent,20 
which increases the risk of toxicity and is costly. This has 
led to consideration of using newer antifungal agents, such 
as voriconazole, posaconazole, and caspofungin, and/or in-
house preparations of these agents as a means to overcome 
the shortcomings of the current therapies.
This review will focus on the use of voriconazole eye 
drops as a treatment for fungal keratitis.
Topical voriconazole  
for fungal keratitis
Voriconazole acts by inhibiting the synthesis of ergosterol 
in the fungal membranes and, ultimately, the growth of the 
microorganism (Figure 1). Voriconazole binds to the active 
site of the P450-dependent enzyme lanosterol 14-demethylase 
(CYP51 or Erg11p) and ligates the iron heme cofactor via 
a nitrogen atom. This results in depletion of ergosterol and 
the accumulation of 14-methyl sterols such as lanosterol, 
affecting the integrity and function of the fungal membrane. 
Voriconazole is a derivative of fluconazole with the addition 
of a methyl group to the propyl backbone and the replacement 
of a triazole moiety with a fluoropyrimidine group, which 
significantly increased the affinity of the compound 
for 14-demethylase and its potency to inhibit CYP51. 
Voriconazole concentrations needed for a 50% decrease in 
ergosterol synthesis (IC50) in fungi extracts of C. albicans 
and C. krusei are 2 and 20 µg/L, respectively, compared with 
10 and 230 µg/L, respectively, with fluconazole. With these 
two fungi, voriconazole is considered to be a more potent 
inhibitor of CYP51 than fluconazole. Similarly, the IC50 
for Aspergillus fumigatus is 0.48 with voriconazole against 
4.8 for fluconazole.81,82
Voriconazole is ideal for use in the treatment of fungal 
keratitis, as it has a broad spectrum of activity with low 
minimum inhibitory concentrations (MIC), as well as a high 
systemic intraocular penetration profile.28,81
Voriconazole is potent against a wide spectrum of 
keratitis-causative fungi, namely, the most common 
pathogens C. albicans, C. parapsilosis, C. tropica-
lis, A. fumigatus, Aspergillus flavus, and Fusarium 
solani,81,84,85 and other less common pathogens from 
the Paecilomyces, Histoplasma, Scedosporium, Curvu-
laria, and Acremonium species.81,84 The in vitro MICs of 
voriconazole against typical keratitis-causative fungi are 
shown in Table 2.
Although the MIC of voriconazole against Fusarium 
species is higher than that for other fungi, compared with 
other antifungal agents, voriconazole has the best activity 
against Fusarium species.86 In a study by Marangon et al,86 
in which the in vitro susceptibility of common pathogens to 
voriconazole was compared with that for amphotericin B, 
fluconazole, itraconazole, and ketoconazole, voriconazole 
demonstrated the lowest MIC90, as shown in Table 3. In 
addition, voriconazole was the only antifungal agent that 
demonstrated 100% antifungal activity against 541 different 
N
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Figure 1 Chemical structure of voriconazole.83Clinical Ophthalmology 2010:4 396
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fungal isolates comprising Candida, Aspergillus, and 
Fusarium species (Figure 2).
Intraocular penetration  
of systemic voriconazole
In a prospective clinical study by Hariprasad et al,67 systemically 
administered voriconazole was demonstrated to achieve 
good penetration into the aqueous and vitreous humors of 
the human eye. Two 12-hourly 400 mg doses of voriconazole 
were administered to 14 patients with noninflamed eyes 
and attending elective surgery. The aqueous and vitreous 
humor samples were collected within three hours after drug 
administration. The mean measured plasma, aqueous, and 
vitreous voriconazole concentrations were 2.13, 1.13, and 
0.81 µg/mL, respectively. The voriconazole concentration in 
the aqueous humor was 53% of the concentration obtained 
in the plasma, and was sufficiently high to be effective 
against most common fungi associated with fungal keratitis. 
A similar outcome was reported by Nulens et al,87 where a 
case of S. apiospermum keratitis was successfully treated 
with oral voriconazole. The voriconazole concentration 
in the aqueous humor (1.8 µg/mL) was measured after 
12 days of drug administration and was also 53% of the 
voriconazole concentration observed in the patient’s plasma 
(3.4 µg/mL). Surprisingly, however, and despite good 
intraocular penetration of oral voriconazole, the reported 
success of oral voriconazole against fungal keratitis may 
not necessarily translate into success against fungal 
infections occurring in the posterior part of the eye (eg, 
endophthalmitis). Indeed, while in the case reported by 
Nulens et al,87 oral voriconazole resulted in a voriconazole 
concentration in the aqueous humor that is sufficient to treat 
S. apiospermum keratitis, in a case report by Nochez et al,88 
the voriconazole concentration in the vitreous humor, result-
ing from oral voriconazole, was not sufficiently high to 
manage successfully an endophthalmitis infection that is also 
caused by S. apiospermum. Concomitant administration of 
intravitreal voriconazole was required to achieve a successful 
outcome.88
Although it has good intraocular penetration, systemic 
voriconazole may result in side effects (including ocular 
events), complications, and interactions with concomitant 
medications.68 Whilst mostly reversible, these side effects 
may lead to the discontinuation of therapy.81 In addition, 
systemic voriconazole is very costly. The cheapest of its 
formulations (ie, oral voriconazole tablets) costs about 
AU$3,000 (US$2,600) per month of therapy for fungal 
keratitis.61 When administered intravenously, it can cost up to 
AU$11,400 (US$9,600) per month.89 Therefore, an efficient 
and economical strategy of using voriconazole for the treat-
ment of fungal keratitis is highly desirable and would be 
invaluable in clinical practice.
Table 2 In vitro minimum inhibitory concentrations (MIC90)   
with voriconazole69,81,96
Organism MIC90 (µg/mL)
Candida albicans 0.06
Candida parapsilosis 0.12–0.25
Candida tropicalis 0.25–16.0
Cryptococcus neoformans 0.06–0.25
Aspergillus fumigates 0.50
Aspergillus flavus 0.50
Fusarium spp. 0.25–8
Fusarium solani 2
Paecilomyces lilacinus 0.50
Acremonium alabamensis 0.25
Blastomyces dermatitidis 0.25
Coccidioides immitis 0.25
Histoplasma capsulatum 0.25
Penicillium marneffei 0.03
Cuvularia spp. 0.06–0.25
Scedosporium spp. 0.5
Scedosporium apiospermum 0.5
Abbreviation: spp, species.
Table 3 In vitro minimum inhibitory concentrations (MIC90) of 
  common antifungals86
Antifungal agent Aspergillus spp.  
(µg/mL)
Candida spp.  
(µg/mL)
Fusarium spp. 
(µg/mL)
Voriconazole 0.5 0.016 2
Amphotericin B 2 0.5 2
Itraconazole 1 0.256 16
Fluconazole 256 0.5 256
Ketoconazole 4 0.032 16
Abbreviation: spp., species.
0 20 40 60 80 100
Voriconazole
Ketoconazole
Amphotericin B
Itraconazole
Fluconazole
All isolates
Figure 2 In vitro susceptibility of 541 fungal isolates to common antifungals.86Clinical Ophthalmology 2010:4 397
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Eye drops and ophthalmic  
drug delivery
The topical administration of medications to the eye is 
a typical strategy for treating disorders of anterior eye 
structures, such as the cornea.90,91 Eye drops are the most 
common dosage form used,91 because they are an economical 
and efficient method of delivering drugs into the eye, and have 
four main advantages.90 Firstly, the drug effect is localized 
where it is needed and a minimal amount of the drug reaches 
the systemic circulation. Secondly, drug concentrations that 
are hard to achieve at the site via systemic administration, 
can be achieved via topical administration. Thirdly, topically 
administered drugs avoid hepatic metabolism. Lastly, topical 
administration is convenient, simple, and painless.
The corneal tissues comprise three major layers of cells, 
ie, a lipophilic outermost layer called the epithelium, a hydro-
philic middle layer called the stroma, and an innermost layer 
of single cells called the endothelium.92,93
Given that the cornea comprises both lipophilic and 
hydrophilic substances, it represents an effective barrier 
against delivering both lipophilic and hydrophilic drugs into 
the eye.90 A lipophilic compound encounters minimal resis-
tance in penetrating the outer epithelium of the cornea, but 
more resistance in infiltrating the stroma. The converse applies 
to hydrophilic compounds, which encounter more resistance 
to absorption from the epithelium and less by the stroma. 
As the corneal epithelium is the main and first barrier to drug 
absorption into the eye,94 it is not surprising that lipophilic 
compounds are more favorable for corneal absorption.90
Formulation of voriconazole  
eye drops
Whilst lipophilic compounds (or drugs) have higher corneal 
permeability, they usually have limited aqueous solubility. 
As such, formulating eye drops for drugs with low aqueous 
solubility can be challenging.90 Voriconazole is a lipophilic 
compound with low solubility (0.061% at pH 7), and is 
unstable in aqueous environments.90,95 For the IV formulation 
of voriconazole to be feasible, the manufacturer encapsulated 
voriconazole with a β-cyclodextrin derivative in the form of 
lyophilized powder of cyclodextrin-voriconazole complex.68 
This increases the solubility and stability of voriconazole in 
aqueous solutions, while maintaining its lipophilicity and 
high corneal permeability.90,94 Cyclodextrins are a group 
of homologous cyclic oligosaccharides that, in complex 
formation with a drug, increase dissolution rate (solubility), 
aqueous stability, and/or bioavailability of the drug.94
Currently, voriconazole eye drops are not commercially 
available, and are aseptically manufactured61,96 by diluting the 
IV formulation of voriconazole. IV voriconazole (Vfend®, 
Pfizer) is available as a glass vial that contains a white lyophi-
lized powder containing 200 mg voriconazole and 3,200 mg 
sulfobutyl ether β-cyclodextrin sodium. As per the voriconazole 
package insert, the powder is reconstituted with 19 mL of water 
for injection to produce a 20 mL aqueous voriconazole solution 
with a concentration of 10 mg/mL (1%).68 This voriconazole 
solution is what is typically being used as eye drops.96,97
Pharmacokinetic data on the corneal penetration of 
topically administered voriconazole are lacking; however, 
a number of studies have suggested good penetration of 
voriconazole through the cornea into the aqueous humor.
Animal studies
Several studies have been performed to assess the penetration 
and tolerability of voriconazole eye drops in animals. In a 
study by Sponsel et al,98 topical voriconazole (5 or 10 µg/mL) 
was evaluated for efficacy against Paecilomyces lilacinus 
keratitis in 10 rabbits (10 infected eyes). Voriconazole 
demonstrated good and deep penetration into the rabbits’ 
eyes. The measured tissue concentrations in the cornea were 
sufficiently high (24.3 and 51 ng/mL with 5 and 10 µg/mL 
voriconazole, respectively), and the experimental keratitis 
was treated successfully.
Topical application of voriconazole eye drops was 
also investigated in a horse model by Clode et al,99 where 
voriconazole eye drops (0.5%, 1.0%, and 3% solutions) 
were administered to seven healthy horses (four eyes for 
each concentration). With the measured aqueous humor 
concentrations being 1.43, 2.35, and 2.4 µg/mL, respectively, 
topical voriconazole was shown to penetrate effectively 
through the cornea and achieve detectable levels.
It is important to recognize, however, that extrapolating 
penetration data from animal models to humans may not be 
reliable. Rabbits, for instance, have a very low blink rate and 
a large epithelial eye surface, which enhances the penetration 
of lipophilic and nonirritating drugs, such as voriconazole, 
into the cornea.100 In addition, while the drainage rate of eye 
drops from the ocular surface in rabbits is about 4 µL per 
minute, it is over twice as much in humans.94
Studies in nonkeratitis patients
Three studies have investigated voriconazole penetration 
through the human cornea into the aqueous humor. Two of 
the studies investigated 1% voriconazole eye drops,61,96 and 
one study investigated 2% voriconazole eye drops.101Clinical Ophthalmology 2010:4 398
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In a prospective study by Vemulakonda et al,96 13 patients 
scheduled for vitrectomy surgery were recruited to receive a 
two-hourly 1% voriconazole eye drop for 24 hours. Samples 
were taken 24 ± 14 minutes after the last dose. Topical vori-
conazole was well tolerated by the eye, and the mean mea-
sured voriconazole concentration in the aqueous humor was 
6.49 ± 3.04 µg/mL, which is sufficiently high to be effective 
against common pathogens. The concentration, however, was 
a peak level concentration, because it was taken 24 minutes 
after a two-hourly dosing regimen (peak concentration is 
reached 20 to 30 minutes after eye drop administration).91 
While this study did not demonstrate that the two-hourly 
dosing regimen results in sustained and adequate therapeutic 
trough voriconazole concentrations in the eye, the ability of 
topically administered voriconazole eye drops to achieve high 
aqueous humor concentrations was demonstrated.
In another prospective study by Lau et al,61 10 patients 
scheduled for anterior segment surgery were recruited to 
receive either a 1% voriconazole eye drop every six hours 
for three days, or every hour for four doses. The eye drops 
were well tolerated, but the aqueous humor concentrations 
achieved were not sufficiently high to be effective against all 
common pathogenic fungi. After the six-hourly and hourly 
dosing, the voriconazole concentrations in the aqueous 
humor were 0.94 ± 1.21 and 1.9 ± 1.12 µg/mL, with average 
sampling times of 2.1 ± 0.6 and 1.1 ± 0.5 hours after the 
last dose, respectively. If samples from the six-hourly 
regimen were to be taken six hours after the last dose (ie, at 
trough level), the concentrations measured would be even 
less than 0.94 µg/mL, suggesting that six-hourly dosing of 
1% voriconazole eye drops may be ineffective. Samples taken 
after hourly dosing were collected approximately one hour 
after the last dose, representing trough level concentrations. 
Although the measured 1.9 µg/mL concentration is effective 
against Aspergillus and Candida keratitis, it is ineffective 
against other common types, such as Fusarium keratitis.
Al-Badriyeh et al investigated the penetration of 
2% voriconazole eye drops,101 with the hypothesis that 
increasing the concentration of voriconazole in the eye 
drops will increase the amount of voriconazole penetrating 
into the eye. Hourly 2% voriconazole eye drops were given 
to 13 human subjects four hours prior to elective anterior 
segment eye surgery. The mean voriconazole concentration 
in the aqueous humor was 1.67 ± 0.97 µg/mL, while the 
mean sampling time after the last eye drop administration 
was at 1.3 ± 0.3 hours. No side effects or toxicities were 
reported. The design of this study was similar to that of Lau 
et al,61 in that both studies had identical numbers and fre-
quencies of doses administered; trough voriconazole levels 
were measured; the same volumes (∼0.05 mL) of eye drops 
were administered at each dose,102 and 0.01% benzalkonium 
chloride solution (a preservative) was used as a diluent for 
the preparation of the eye drops. It should be noted that the 
clinical studies by Lau et al,61 and Al-Badriyeh et al,101 are 
the only studies in the literature that involved the use of 
benzalkonium chloride solution. Benzalkonium chloride 
is a quaternary ammonium compound with a broad range 
of antimicrobial activity.103 It is the most frequently used 
preservative in ophthalmic solutions, and its concentration 
ranges from 0.004 to 0.02%.103 In addition to preventing 
microbial contamination, benzalkonium chloride is known 
to act as a corneal penetrating enhancer, promoting drug 
penetration through the strong corneal barrier.104 The study by 
Al-Badriyeh et al found that the concentration of voriconazole 
in the aqueous humor resulting from the 2% voriconazole 
eye drops was not significantly different from that reported 
for the 1% solution,61,101 suggesting that the penetration of 
voriconazole through an intact infection-free cornea is not 
concentration-dependent, at least for the concentration range 
studied. This appears to be counterintuitive to the hypoth-
esis of the study but is consistent with data from the horse 
model by Clode et al,99 in which the voriconazole level in the 
corneas of horses with fungal keratitis did not change when 
the concentration of the administered voriconazole eye drops 
was changed from 1% to 3%.
The studies by Vemulakonda et al, Lau et al, and 
Al-Badriyeh et al explored the penetration of voriconazole eye 
drops into the human aqueous humor using different dosage 
regimens and concentrations.61,96, 101 However, it is important 
to recognize the major limitation of these studies, ie, that 
the eye drops were applied to noninfected eyes. It has been 
widely observed that corneal drug penetration will generally 
be enhanced with the destruction of the corneal epithelium.105 
For instance, the removal of the surface of the corneal epithe-
lium is recommended to improve the penetration of topical 
amphotericin B.100 On the other hand, in the rabbit model by 
Sponsel et al,98 when the penetration of topical voriconazole 
into the infected eyes was compared with penetration into the 
noninfected eyes of the rabbits, it was found that the corneal 
concentration of voriconazole in the noninfected eyes (after 
topical administration) was higher than that in the infected 
corneas. However, in a recent case series by Thiel et al (where 
voriconazole concentrations in the aqueous humor, following 
the administration of voriconazole eye drops, were compared 
among patients with different degrees of corneal injuries) 
voriconazole concentrations in the infected eyes depended Clinical Ophthalmology 2010:4 399
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neither on the size of the epithelial defect nor on epithelial 
removal.100 These, however, are preliminary findings, and the 
effect of corneal damage on the penetration of voriconazole 
into the human eye remains to be fully elucidated.
Studies in keratitis patients
To date, the penetration of topical voriconazole eye drops 
through the infected cornea in humans has only been reported 
twice, and in the form of case reports. In the case reported by 
Klont et al,69 the aqueous humor voriconazole concentration 
was measured after 13 days of topical 1% voriconazole, 
co-administered with oral voriconazole, for the treat-
ment of a patient with Fusarium keratitis. The advantage 
of topical voriconazole was demonstrated by an aqueous 
humor concentration of 3.2 µg/mL, which was 160% of 
the voriconazole concentration in plasma (2 µg/mL). In the 
previously mentioned case series by Thiel et al,100 six patients, 
including five patients with fungal keratitis, received IV and 
topical voriconazole for the treatment of Aspergillus and 
Candida infections. The aqueous humor samples were col-
lected at stages of therapy where voriconazole eye drops were 
used alone, yielding voriconazole concentrations ranging 
from 0.61 to 3.3 µg/mL. The results were highly variable, 
but provided support for the benefit of using voriconazole 
eye drops.
Efficacy
Although voriconazole concentrations were detected in the 
aqueous humor after topical administration of voriconazole 
eye drops, this may not necessarily correlate with efficacy 
in the clinical setting of fungal keratitis.20 Well-designed 
clinical studies of voriconazole eye drops in patients with 
active fungal keratitis are difficult to perform and, therefore, 
lacking. The difficulties in conducting such studies relate 
to the low incidence of fungal keratitis as well as the need 
for long treatment duration. In addition, in clinical settings, 
patients will mostly be receiving other antifungal therapies 
that will interfere with the outcomes measured.
Currently, evidence of the clinical efficacy of voriconazole 
eye drops in fungal keratitis is based solely on case reports. 
A review of the published literature identified nine reports 
on the use of voriconazole eye drops for the treatment of 
fungal keratitis.69,74,106–111 The case reports are summarized in 
Table 4.
In most of the reported cases, voriconazole eye drops were 
used in combination with systemic voriconazole, except for 
the case reports by Al-Badriyeh et al,110,111 where voriconazole 
eye drops were used as monotherapy. Voriconazole 1% eye 
drops were used in all cases, except in the case reported by 
Polizzi et al,106 where 2% voriconazole was used. Brief sum-
maries of these cases are given below.
The first of these cases, reported by Reis et al,108 involved 
a 16-year-old girl diagnosed with keratitis caused by F. solani 
after swimming in a lake. After months of antifungal therapy, 
the fungal keratitis failed to respond. The patient was initially 
prescribed topical amphotericin B and fluconazole, followed 
by itraconazole at a later stage. These, however, had no effect 
on the infection and, hence, IV voriconazole followed by oral 
voriconazole was administered. A significant improvement 
was noticed, followed by resolution upon the addition of 
topical voriconazole to therapy, which was discontinued 
after eight weeks.
The case report by Klont et al also reported the use of 
1% voriconazole eye drops in the treatment of Fusarium 
keratitis.69 A 23-year-old man with F. solani keratitis failed 
to respond to treatment despite initial topical amphotericin B   
and itraconazole. The patient was then prescribed, as salvage 
therapy, concomitant IV and topical voriconazole followed 
by oral and topical voriconazole. The treatment was ceased 
at week 6, with a successful outcome.
In the case report by Prats et al,107 a 19-year-old man 
was admitted with an incisive eye wound, with the cornea 
totally sectioned upon trauma. S. apiospermum keratitis 
was diagnosed. Upon failure of initial empirical antifungal 
therapy, systemic (IV and oral) and topical voriconazole 
were commenced. The infection resolved, and the eye did not 
have to be enucleated. This was the first case report where 
voriconazole was used for the treatment of S. apiospermum 
keratitis. Five months after the incident, a penetrating 
keratoplasty and chamber intraocular lens implantation was 
performed with a favorable visual outcome.
Jones et al demonstrated that voriconazole was effective 
in a 52-year-old woman diagnosed with Aspergillus 
niger keratitis.109 The patient was initially treated with 
topical amphotericin B, which was not effective. When the 
patient was switched to a combination of oral and topical 
voriconazole, the infection improved rapidly and resolved 
after five weeks.
In the first of the two cases reported by Tu et al,74 a 
29-year-old man received oral and topical voriconazole for 
the treatment of trauma-induced Fusarium keratitis. In the 
second case, a 43-year-old woman received a combination 
of IV, topical, and intravitreal voriconazole for keratitis 
caused by F. solani that was associated with contact lens 
wear. In both of these cases, voriconazole was initially 
effective until it had to be discontinued because of severe Clinical Ophthalmology 2010:4 400
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hepatotoxicity. Patients were then switched to posaconazole 
as salvage therapy.
In the two case reports by Al-Badriyeh et al,110,111 1% 
voriconazole was used as a stand-alone therapy. In one case 
report,110 a 54-year-old woman presented with a painful 
injected eye. Despite empirical therapy, symptoms per-
sisted. Keratitis was later diagnosed and identified as a rare 
S. apiospermum keratitis. Primary antifungal therapy with 
natamycin 5% was not successful and was switched to 1% 
voriconazole eye drops. Vision improved in five days, and 
the corneal defect completely re-epithelialized in a week. 
In the other report by Al-Badriyeh et al,111 a 48-year-old 
presented with keratitis following exposure to dust, the 
cause of which was later identified as C. albicans. Despite 
empirical antibacterial therapy, the epithelial defect persisted. 
Primary antifungal therapy with 1% voriconazole eye drops 
was initiated. The corneal infiltrate resolved in two days, 
the epithelial defect was completely healed, and visual acuity 
was restored in seven days.
Polizzi et al reported the only case where 2% voriconazole 
eye drops were used.106 A 56-year-old man developed corneal 
ulceration caused by F. solani upon accidental contact with 
vegetation. Corneal ulceration developed and a perforating 
keratoplasty was performed. Systemic and topical ampho-
tericin B and fluconazole were administered initially, but the 
patient did not improve. A new abscess formed on the trans-
planted graft and a wound leak developed. Therapy was then 
switched to IV and oral voriconazole in combination with 
topical 2% voriconazole eye drops. The patient completely 
recovered after 20 days of treatment with voriconazole.
A number of important considerations are associated with 
the above cases. One is that the use of voriconazole eye drops 
was associated with successful outcomes in most cases of 
fungal keratitis. Whilst the voriconazole therapy appeared to 
Table 4 Case reports of the use of topical voriconazole in fungal keratitis69,74,106–111
Author Patient  
(age, sex)
Pathogen Voriconazole 
concentration
Treatment Outcome Systemic voriconazole
Reis et al 16, female Fusarium solani 1% Salvage Success Intravenous voriconazole 6 mg/kg 
twice daily on day 1, followed by 
intravenous voriconazole 4 mg/kg   
twice daily until day 11. Oral  
  voriconazole 6 mg/kg twice daily 
was then given for eight weeks
Klont et al 23, male Fusarium solani 1% Salvage Success Intravenous voriconazole 6 mg/kg   
twice daily on day 1, followed by  
intravenous voriconazole 4 mg/kg   
twice daily for two weeks. Oral  
voriconazole 200 mg twice daily  
was then given for two weeks
Prats et al 19, male Scedosporium  
apiospermum
1% Salvage Success Oral voriconazole 200 mg  
twice daily for six weeks
Jones et al 52, female Aspergillus niger 1% Salvage Success Oral voriconazole 200 mg  
twice daily for five weeks
Tu et al 29, male Fusarium species 1% Primary Failure Oral voriconazole 200 mg  
twice daily for five weeks
Tu et al 43, female Fusarium solani 1% Primary Failure Intravenous voriconazole 200 mg  
twice daily on day 1, followed by  
oral voriconazole 200 mg twice  
daily for six weeks
Al-Badriyeh et al 54, female Scedosporium  
apiospermum
1% Salvage Success None
Al-Badriyeh et al 48, male Candida albicans 1% Primary Success None
Polizzi et al 56, male Fusarium solani 2% Salvage Success Intravenous voriconazole 400 mg  
twice daily on day 1, followed by  
intravenous voriconazole 300 mg  
twice daily until day 15. Oral  
  voriconazole 200 mg twice daily  
was then given for four weeksClinical Ophthalmology 2010:4 401
Voriconazole eye drops in fungal keratitis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
fail in the cases reported by Tu et al,74 the failure was not due 
to lack of efficacy, but to severe side effects from systemically 
administered voriconazole, which required discontinuation 
of treatment. A second issue is that voriconazole eye drops 
were used as an adjunct to systemic voriconazole in most 
reported cases. Only Al-Badriyeh et al have demonstrated 
the clinical benefit of topical voriconazole when used alone 
as primary and salvage therapies.110,111 Thirdly, whilst the 2% 
voriconazole eye drops were effective,106 the advantage of 
using 2% compared with 1% voriconazole eye drops remains 
unknown. A fourth issue is that, in the reports by Al-Badriyeh 
et al,110,111 the voriconazole eye drops were prepared as a solu-
tion containing 0.01% benzalkonium chloride as preservative, 
whereas, in all other case reports, the eye drops were prepared 
in sterile water for injection. In these case reports, voricon-
azole eye drops were typically administered with a dosing 
frequency of one drop every 0.5, 1.0, or 2.0 hours,69,74,106–111 and 
the average duration of administration of the voriconazole eye 
drops as adjunct therapy (ie, one to two months) was similar 
to the average duration of administration of the voriconazole 
eye drops given as monotherapy (ie, one month). However, it 
is common for the administration of the eye drops to extend 
beyond the resolution of fungal keratitis, with a duration that 
is more related to local clinical practices rather than time to 
resolution.
Safety
The safety of voriconazole in the eye was first evaluated in a 
rat model by Gao et al,85 who demonstrated that intravitreal 
voriconazole concentration as high as 25 mg/mL did not 
result in any electroretinographic or histologic abnormalities 
in the rat retina. This, however, cannot be extrapolated as an 
evidence of the safety of voriconazole when topically applied 
to the human cornea.
In a stability study by Al-Badriyeh et al,112 changes in the 
pH of 1% and 2% voriconazole eye drops were followed for 
over three months, and were found to range between 6.02 and 
6.27. This was consistent with the findings of the only other 
stability study of voriconazole eye drops, performed by Dupuis 
et al,97 where a pH of 7 was maintained for 1% voriconazole 
eye drops with a storage duration of 30 days. These pH values 
are usually well tolerated by the eye.112 It is unlikely, therefore, 
that any eye irritation resulting from the use of the voriconazole 
eye drops would be a consequence of low pH.
Indeed, in the above studies that evaluated the application 
of voriconazole eye drops to the eye of animals and humans, 
the drops were well tolerated, and associated with mild or no 
side effects. In the animal model by Sponsel et al,98 all rabbits 
responded well to the voriconazole eye drops with no apparent 
side effects. In the horse model by Clode et al,99 0.5% and 
1% voriconazole eye drops resulted in no side effects, and 
only the higher 3% concentration was associated with ocular 
toxicity. In the clinical study by Vemulakonda et al,96 only 
two patients reported a mild transient stinging sensation on 
instillation of the 1% voriconazole eye drops. Visualization 
was excellent in all 13 patients. Of the 10 patients in the study 
by Lau et al,61 four patients reported one or two instances 
of mild stinging, and one patient reported sneezing after 
the initial dose. None of the patients in the clinical study 
by Al-Badriyeh et al reported any side effects with the 2% 
voriconazole eye drops.101 These outcomes were consistent 
with the outcome in another study by Lau et al that evaluated 
voriconazole penetration into the vitreous humor of the eye 
after topical application of the eye drops.113 Here also, no side 
effects were reported. Similarly, in all of the case reports of 
using topical voriconazole in fungal keratitis, the eye drops 
were well tolerated with no side effects reported.69, 74,106–111
Systemic side effects resulting from the topical 
administration of the voriconazole solution should be 
negligible. In the case of the 2% eye drops (the highest 
concentration that has been reported in humans), each 
drop contains only 0.001 mg of voriconazole which, when 
compared with the standard systemic dose of 200 mg oral or 
IV voriconazole twice daily,68 is unlikely to result in systemic 
concentration that is high enough to induce side effects.
Stability of voriconazole eye drops
According to the stability study by Al-Badriyeh et al,112 
1% voriconazole eye drops, prepared in sterile benzalkonium 
chloride 0.01% solution, were stable for at least 14 weeks 
when stored at 2–8°C, while 2% voriconazole eye drops, 
also prepared in sterile benzalkonium chloride solution, 
were stable for 16 weeks at 2–8, 25, and 40°C. This was 
consistent with the stability study by Dupuis et al,97 where 
1% voriconazole eye drops, prepared in sterile water for 
injection, were stable for at least four weeks when stored at 
4°C. Such long-term stability data will help minimize wast-
age and is pivotal to facilitate the use of the eye drops in the 
outpatient setting.
Patient adherence and satisfaction
Given the observed efficacy, safety, and stability, voriconazole 
eye drops appear to be a good option in the treatment of fun-
gal keratitis. However, non-adherence to the prescribed dos-
ing regimen may pose a challenge to achieving the desired 
treatment outcome and, consequently, lead to progression of Clinical Ophthalmology 2010:4 402
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the infection. The benefits of using voriconazole eye drops, 
especially in the outpatient setting, could be diminished due 
to poor patient adherence if the dosing regimen is intense 
(eg, hourly to two-hourly drops) and is for an extended 
duration. The outpatient setting is different from the situation 
in clinical studies, in which maximal compliance can be 
achieved because the eye drops are often administered by 
nursing staff in hospitals.100 To date, there are no published 
data available about patient adherence to voriconazole eye 
drops.
The appropriate dosing frequency of voriconazole 
eye drops is not clear. The voriconazole aqueous 
humor concentration measured by Vemulakonda et al 
(6.49 ± 3.04 mg/L),96 where 1% eye drops were administered 
every two hours for 24 hours, is more than three times the 
concentration reported by Lau et al (1.90 ± 1.12 mg/L),61 
where one drop was administered every hour for four hours. 
Based on these data, it is tempting to assume that the higher 
concentration measured by Vemulakonda et al was a result 
of drug accumulation in the eye; however, the significant 
difference in the post-dose sampling time (0.4 hours versus 
1.1 hours in the Vemulakonda et al and Lau et al studies, 
respectively) could have been the key factor behind the 
differences in the measured voriconazole level in the aque-
ous humor.
Conclusion
Voriconazole eye drops appear to be effective when used 
for the treatment of fungal keratitis caused by a variety of 
fungi, including F. solani, C. albicans, S. apiospermum, and 
A. niger. The eye drops are well tolerated in the reported 
clinical trials and case studies. In addition, stability data 
for the extemporaneously prepared eye drops are available, 
minimizing the manufacturing cost and wastage associated 
with the eye drops.
Case reports have shown that voriconazole eye drops are 
effective when used as adjunctive therapy or monotherapy, 
and as primary or salvage therapy for the management 
of ophthalmic fungal keratitis. However, the number of 
these case reports and, hence, their significance remains 
limited. Whilst large-scale, randomized, controlled stud-
ies are needed, such studies are difficult to conduct and, 
consequently, audits or large case series on the use of 
voriconazole eye drops as monotherapy are necessary to 
confirm current findings and help establish the extent of 
their effectiveness.
Increasing the concentration of voriconazole eye drops 
may lead to increased efficacy and/or reduced dosing 
frequency; however, the benefit of using concentrations 
greater than 1% has not been evaluated in patients with 
fungal keratitis beyond a single case report. Studies using 
intact corneas have suggested concentration-independent 
penetration of voriconazole through the cornea and, 
consequently, it appears that administering 2% over 
1% voriconazole eye drops in fungal keratitis is unlikely 
to give any additional benefit. Although some studies 
have suggested that epithelial damage is not necessary 
for voriconazole penetration, future studies that evaluate 
the penetration of 2% versus 1% voriconazole eye drops 
in patients with fungal keratitis, despite being difficult to 
perform, will be important. Given that the optimal dosing 
of the voriconazole eye drops remains unknown, studies to 
investigate the extent of voriconazole clearance from the 
human eye after topical administration should be conducted 
to guide the dosing frequency.
Current literature has provided some evidence on the 
effectiveness of voriconazole eye drops for the treatment of 
fungal keratitis; however, more data are required before a 
definite conclusion regarding their utility is drawn.
Disclosures
The authors report no financial or other conflicts of interest 
in this work.
References
  1.  Whitcher J, Srinivasan M, Upadhyay M. Corneal blindness: A global 
perspective. Bull World Health Organ. 2001;79(3):214–221.
  2.  Dandona L, Dandona R, Naduvilath T, et al. Is current eye-care-policy 
focus almost exclusively on cataract adequate to deal with blindness in 
India? Lancet. 1998;351(9112):1312–1316.
  3.  Levin L, Avery R, Shore J, Woog J, Baker A. The spectrum of 
orbital aspergillosis: A clinicopathological review. Surv Ophthalmol. 
1996;41(2):142–154.
  4.  Yohai R, Bullock J, Aziz A, Markert R. Survival factors in rhino-
  orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39(1):3–22.
  5.  See J, Wong T, Yeo K. Trends in the pattern of blindness and major 
ocular diseases in Singapore and Asia. Ann Acad Med Singapore. 
1998;27(4):540–546.
  6.  Hagan M, Wright E, Newman M, Dolin P, Johnson G. Causes of 
suppurative keratitis in Ghana. Br J Ophthalmol. 1995;79(11): 
1024–1028.
  7.  Puttanna S. Primary keratomycosis. J All India Ophthalmol Soc. 
1969;17(5):171–200.
  8.  Galarreta D, Tuft S, Ramsay A, Dart J. Fungal keratitis in London: 
Microbiological and clinical evaluation. Cornea. 2007;26(9):1082–1086.
  9.  Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15(4): 
321–327.
  10.  Bhartiya P, Daniell M, Constantinou M, Islam F, Taylor H. Fungal 
keratitis in Melbourne. Clin Experiment Ophthalmol. 2007;35(2): 
124–130.
  11.  Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical 
aspects of Fusarium species. Clin Microbiol Rev. 1994;7(4):479–504.
  12.  Thomas P. Mycotic keratitis – an underestimated mycosis. J Med Vet 
Mycol. 1994;32(4):235–256.Clinical Ophthalmology 2010:4 403
Voriconazole eye drops in fungal keratitis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  13.  Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao G. 
The epidemiological features and laboratory results of fungal keratitis: 
A 10-year review at a referral eye care center in South India. Cornea. 
2002;21(6):555–559.
  14.  Rosa R, Miller D, Alfonso E. The changing spectrum of fungal keratitis 
in south Florida. Ophthalmology. 1994;101(6):1005–1013.
  15.  Cuero RG. Ecological distribution of Fusarium solani and its 
opportunistic action related to mycotic keratitis in Cali, Colombia.   
J Clin Microbiol. 1980;12(3):455–461.
  16.  Stevens D, Kan V, Judson M, et al. Practice guidelines for diseases 
caused by aspergillus. Infectious Diseases Society of America. 
Clin Infect Dis. 2000;30(4):696–709.
  17.  Tabbara K, al Jabarti A. Hospital construction-associated outbreak 
of ocular aspergillosis after cataract surgery. Ophthalmology. 
1998;105(3):522–526.
  18.  Smolin G, Foster CS, Azar DT, Dohlman CH. The Cornea: Scientific 
Foundations and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott 
Williams & Wilkins Inc.; 2005.
  19.  Klintworth G. The cornea – structure and macromolecules in health 
and disease. A review. Am J Pathol. 1977;89(3):718–808.
  20.  Thomas PA. Current perspectives on ophthalmic mycoses. Clin 
Microbiol Rev. 2003;16(4):730–797.
  21.  Gordon M, Norton S. Corneal transplant infection by Paecilomyces 
lilacinus. Sabouraudia. 1985;23(4):295–301.
  22.  Kozarsky A, Stulting R, Waring G, Cornell F, Wilson L, Cavanagh H. 
Penetrating keratoplasty for exogenous Paecilomyces keratitis followed by 
postoperative endophthalmitis. Am J Ophthalmol. 1984;98(5):552–557.
  23.  Fincher R, Fisher J, Lovell R, Newman C, Espinel-Ingroff A, Shadomy H.   
Infection due to the fungus Acremonium (cephalosporium). Medicine 
(Baltimore). 1991;70(6):398–409.
  24.  Guarro J, Gams W, Pujol I, Gene J. Acremonium species: New emerging 
fungal opportunists – in vitro antifungal susceptibilities and review. 
Clin Infect Dis. 1997;25(5):1222–1229.
  25.  Garg P, Gopinathan U, Choudhary K, Rao G. Keratomycosis: Clinical 
and microbiologic experience with dematiaceous fungi. Ophthalmology. 
2000;107(3):574–580.
  26.  Jones B. Principles in the management of oculomycosis. XXXI Edward 
Jackson memorial lecture. Am J Ophthalmol. 1975;79(5):719–751.
  27.  Stern G, Buttross M. Use of corticosteroids in combination with 
antimicrobial drugs in the treatment of infectious corneal disease. 
Ophthalmology. 1991;98(6):847–853.
  28.  Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. 
Voriconazole in the treatment of fungal eye infections: A review of 
current literature. Br J Ophthalmol. 2008;92(7):871–878.
  29.  Fairley C, Sullivan T, Bartley P, Allworth T, Lewandowski R. Survival 
after rhino-orbital-cerebral mucormycosis in an immunocompetent 
patient. Ophthalmology. 2000;107(3):555–558.
  30.  Marshall D, Brownstein S, Jackson W, Mintsioulis G, Gilberg S, 
al-Zeerah B. Post-traumatic corneal mucormycosis caused by Absidia 
corymbifera. Ophthalmology. 1997;104(7):1107–1011.
  31.  Mino de Kaspar H, Zoulek G, Paredes M, et al. Mycotic keratitis in 
Paraguay. Mycoses. 1991;34(5–6):251–254.
  32.  Panda A, Sharma N, Das G, Kumar N, Satpathy G. Mycotic keratitis 
in children: Epidemiologic and microbiologic evaluation. Cornea. 
1997;16(3):295–299.
  33.  Tanure M, Cohen E, Sudesh S, Rapuano C, Laibson P. Spectrum of 
fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. 
Cornea. 2000;19(3):307–312.
  34.  Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetio-
logical diagnosis of corneal ulceration in Madurai, south India. Br J 
Ophthalmol. 1997;81(11):965–971.
  35.  Sony P, Sharma N, Vajpayee R, Ray M. Therapeutic keratoplasty for infec-
tious keratitis: A review of the literature. CLAO J. 2002;28(3):111–118.
  36.  Dunlop A, Wright E, Howlader S, et al. Suppurative corneal ulceration 
in Bangladesh. A study of 142 cases examining the microbiological 
diagnosis, clinical and epidemiological features of bacterial and fungal 
keratitis. Aust N Z J Ophthalmol. 1994;22(2):105–110.
  37.  Wong T, Ng T, Fong K, Tan D. Risk factors and clinical outcomes 
between fungal and bacterial keratitis: A comparative study. CLAO J. 
1997;23(4):275–281.
  38.  Clinch T, Robinson M, Barron B, Insler M, Liang K, Kaufman H. 
Fungal keratitis from nylon line lawn trimmers. Am J Ophthalmol. 
1992;114(4):437–440.
  39.  Okhravi N, Dart JK, Towler HM, Lightman S. Paecilomyces lilacinus 
endophthalmitis with secondary keratitis: A case report and literature 
review. Arch Ophthalmol. 1997;115(10):1320–1324.
  40.  Manzouri B, Vafidis G, Wyse R. Pharmacotherapy of fungal eye 
infections. Expert Opin Pharmacother. 2001;2(11):1849–1857.
  41.  FlorCruz NV, Peczon Jr I. Medical interventions for fungal keratitis. 
Cochrane Database Syst Rev. 2008;CD004241.
  42.  O’Day D. Selection of appropriate antifungal therapy. Cornea. 
1987;6(4):238–245.
  43.  Khoo SH, Bond J, Denning DW. Administering amphotericin B – a 
practical approach. J Antimicrob Chemother. 1994;33(2):203–213.
  44.  Bates D, Su L, Yu D, et al. Mortality and costs of acute renal failure 
associated with amphotericin B therapy. Clin Infect Dis. 2001;32(5): 
686–693.
  45.  O’Day D, Head W, Robinson R, Clanton J. Corneal penetration of 
topical amphotericin B and natamycin. Curr Eye Res. 1986;5(11): 
877–882.
  46.  O’Brien TP. Therapy of ocular fungal infections. Ophthalmol Clin 
North Am. 1999;12:33–50.
  47.  Natacyn [Package insert]. Alcon Laboratories Inc., Texas, May 2008.
  48.  Panda A, Sharma N, Angra S. Topical fluconazole therapy of Candida 
keratitis. Cornea. 1996;15(4):373–375.
  49.  Seal D, Pleyer U. Ocular Infection and Immunity. 2nd ed. New York, 
NY: Informa Healthcare Inc.; 2007.
  50.  Ganegoda N, Rao SK. Antifungal therapy for keratomycoses. Expert 
Opin Pharmacother. 2004;5(4):865–874.
  51.  O’Day D, Head W, Robinson R, Williams T, Gedde S. Anomalous 
effect of subconjunctival miconazole on Candida albicans keratitis in 
rabbits. Am J Ophthalmol. 1991;112(5):562–566.
  52.  Torres MA, Mohamed J, Cavazos-Adame H, Martinez LA. Topical 
ketoconazole for fungal keratitis. Am J Ophthalmol. 1985;100(2): 
293–298.
  53.  Foster CS, Lass JH, Moran-Wallace K, Giovanoni R. Ocular toxicity of 
topical antifungal agents. Arch Ophthalmol. 1981;99(6):1081–1084.
  54.  Foster CS, Stefanyszyn M. Intraocular penetration of miconazole in 
rabbits. Arch Ophthalmol. 1979;97(9):1703–1706.
  55.  Thomas PA. Fungal infections of the cornea. Eye (Lond). 2003;17(8): 
852–862.
  56.  Prajna NV, John RK, Nirmalan PK, Lalitha P, Srinivasan M. 
A randomised clinical trial comparing 2% econazole and 5% 
natamycin for the treatment of fungal keratitis. Br J Ophthalmol. 
2003;87(10):1235–1237.
  57.  Avunduk A, Beuerman R, Warnel E, Kaufman H, Greer D. Comparison 
of efficacy of topical and oral fluconazole treatment in experimental 
Aspergillus keratitis. Curr Eye Res. 2003;26(2):113–117.
  58.  Nunery W, Welsh M, Saylor R. Pseudallescheria boydii (Petriellidium 
boydii) infection of the orbit. Ophthalmic Surg. 1985;16(5):296–300.
  59.  Sonego-Krone S, Sanchez-Di Martin D, Ayala-Lugo R, et al. Clinical 
results of topical fluconazole for the treatment of filamentous fungal 
keratitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(7):782–787.
  60.  Tu E. Alternaria keratitis: Clinical presentation and resolution 
with topical fluconazole or intrastromal voriconazole and topical 
caspofungin. Cornea. 2009;28(1):116–119.
  61.  Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1%, 
eyedrops into human aqueous humor: A prospective open-label study. 
Arch Ophthalmol. 2008;126(3):343–346.
  62.  Rao S, Madhavan H, Rao G, Padmanabhan P. Fluconazole in 
filamentous fungal keratitis. Cornea. 1997;16(6):700.
  63.  Rajasekaran J, Thomas P, Kalavathy C, Joseph P, Abraham D. Itra-
conazole therapy for fungal keratitis. Indian J Ophthalmol. 1987; 
35(5–6):157–160.Clinical Ophthalmology 2010:4 404
Al-Badriyeh et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  64.  Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new 
azole compounds into the eye and efficacy in experimental Candida 
endophthalmitis. Antimicrob Agents Chemother. 1987;31(1):6–10.
  65.  Vanden Bossche H, Mackenzie D, Cauwenbergh G. Aspergillus and 
Aspergillosis. New York, NY: Plenum Press Inc.; 1988.
  66.  Johnson L, Kauffman C. Voriconazole: A new triazole antifungal agent. 
Clin Infect Dis. 2003;36(5):630–637.
  67.  Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, 
aqueous, and plasma concentration of orally administered voriconazole 
in humans. Arch Ophthalmol. 2004;122(1):42–47.
  68.  Vfend [Package insert]. New York, NY: Pfizer Inc.; March 2008.
  69.  Klont R, Eggink C, Rijs A, Wesseling P, Verweij P. Successful treat-
ment of Fusarium keratitis with cornea transplantation and topical and 
systemic voriconazole. Clin Infect Dis. 2005;40(12):e110–e112.
  70.  Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: An 
electroretinographic and histopathologic study. Arch Ophthalmol. 
2004;122(11):1687–1692.
  71.  Torres H, Hachem R, Chemaly R, Kontoyiannis D, Raad I. 
Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis. 
2005;5(12):775–785.
  72.  Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, 
safety, and efficacy of posaconazole in patients with persistent febrile 
neutropenia or refractory invasive fungal infection. Antimicrob Agents 
Chemother. 2006;50(2):658–666.
  73.  Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and 
systemic posaconazole (SCH-56592) treatment of invasive Fusarium 
solani keratitis and endophthalmitis. Br J Ophthalmol. 2002;86(7): 
829–830.
  74.  Tu E, McCartney D, Beatty R, Springer K, Levy J, Edward D. Successful 
treatment of resistant ocular fusariosis with posaconazole (SCH-56592). 
Am J Ophthalmol. 2007;143(2):222–227.
  75.  Abdel-Rahman S, Nahata M. Oral terbinafine: A new antifungal agent. 
Ann Pharmacother. 1997;31(4):445–456.
  76.  Jensen J. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp 
Dermatol. 1989;14(2):110–113.
  77.  Nedelman JR, Gibiansky E, Robbins B, et al. Pharmacokinetics and 
pharmacodynamics of multiple-dose terbinafine. J Clin Pharmacol. 
1996;36(5):452–461.
  78.  Liang QF, Jin XY, Wang XL, Sun XG. Effect of topical application 
of terbinafine on fungal keratitis. Chin Med J (Engl). 2009;122(16): 
1884–1888.
  79.  Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S. Topical 
caspofungin for treatment of keratitis caused by Candida albicans in a 
rabbit model. Antimicrob Agents Chemother. 2005;49(4):1359–1363.
  80.  Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility 
of fusarium, aspergillus, and other filamentous fungi isolated from 
keratitis. Arch Ophthalmol. 2007;125(6):789–793.
  81.  Jurkunas U, Langston D, Colby K. Use of voriconazole in the treatment 
of fungal keratitis. Int Ophthalmol Clin. 2007;47(2):47–59.
  82.  Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics 
of voriconazole. Int J Antimicrob Agents. 2006;27(4):274–284.
  83.  Carrillo-Munoz A, Quindos G, JL LR. Current development in anti-
fungal agents. Curr Med Chem. 2004;3(4):297–323.
  84.  Breit S, Hariprasad S, Mieler W, Shah G, Mills M, Grand M. 
Management of endogenous fungal endophthalmitis with voriconazole 
and caspofungin. Am J Ophthalmol. 2005;139(1):135–140.
  85.  Gao H, Pennesi M, Shah K, et al. Safety of intravitreal voriconazole: 
Electroretinographic and histopathologic studies. Trans Am Ophthalmol 
Soc. 2003;101:183–189.
  86.  Marangon F, Miller D, Giaconi J, Alfonso E. In vitro investigation of 
voriconazole susceptibility for keratitis and endophthalmitis fungal 
pathogens. Am J Ophthalmol. 2004;137(5):820–825.
  87.  Nulens E, Eggink C, Rijs AJMM, Wesseling P, Verweij PE. Keratitis 
caused by Scedosporium apiospermum successfully treated with a cornea 
transplant and voriconazole. J Clin Microbiol. 2003;41(5):2261–2264.
  88.  Nochez Y, Arsene S, Le Guellec C, et al. Unusual pharmacokinetics 
of intravitreal and systemic voriconazole in a patient with 
Scedosporium apiospermum endophthalmitis. J Ocul Pharmacol Ther. 
2008;24(1):87–90.
  89.  Stewart A, Powles R, Hewetson M, Antrum J, Richardson C, Mehta J. 
Costs of antifungal prophylaxis after bone marrow transplantation. 
A model comparing oral fluconazole, liposomal amphotericin and 
oral polyenes as prophylaxis against oropharyngeal infections. 
Pharmacoeconomics. 1995;8(4):350–361.
  90.  Davies N. Biopharmaceutical considerations in topical ocular drug 
delivery. Clin Exp Pharmacol Physiol. 2000;27(7):558–562.
  91.  Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug 
delivery. Adv Drug Deliv Rev. 2006;58(11):1131–1135.
  92.  Forrester JV, Dick AD, Roberts F. The Eye: Basic Sciences in Practice: 
Basic Science in Practice. 2nd ed. London, UK: Saunders Ltd; 2002.
  93.  Klotz S, Penn C, Negvesky G, Butrus S. Fungal and parasitic infections 
of the eye. Clin Microbiol Rev. 2000;13(4):662–685.
  94.  Jtirvinen K, Urtti A. Ocular absorption following topical delivery. Adv 
Drug Del Rev. 1995;16(1):3–19.
  95.  Silveira FP, Husain S. Fungal infections in solid organ transplantation. 
Med Mycol. 2007;45(4):305–320.
  96.  Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, 
Van Gelder RN. Aqueous and vitreous concentrations following topical 
administration of 1% voriconazole in humans. Arch Ophthalmol. 
2008;126(1):18–22.
  97.  Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability 
of voriconazole eye drop solution. Antimicrob Agents Chemother. 
2009;53(2):798–799.
  98.  Sponsel W, Chen N, Dang D, et al. Topical voriconazole as a 
novel treatment for fungal keratitis. Antimicrob Agents Chemother. 
2006;50(1):262–268.
  99.  Clode A, Davis J, Salmon J, Michau T, Gilger B. Evaluation of 
concentration of voriconazole in aqueous humor after topical and oral 
administration in horses. Am J Vet Res. 2006;67(2):296–301.
  100.  Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. 
Voriconazole concentration in human aqueous humor and plasma 
during topical or combined topical and systemic administration 
for fungal keratitis. Antimicrob Agents Chemother. 2007;51(1): 
239–244.
  101.  Al-Badriyeh D, Leung L, Roydhouse T, et al. Prospective open-label 
study of the administration of two-percent voriconazole eye drops. 
Antimicrob Agents Chemother. 2009;53(7):3153–3155.
  102.  Lau D. Penetration of 1% voriconazole eye drops into human aqueous 
and vitreous humor – a prospective, open-label study (MClinPharm 
thesis). Melbourne, Australia: Monash University; 2006.
  103.  Freeman PD, Kahook MY. Preservatives in topical ophthalmic medica-
tions: Historical and practical review of benzalkonium chloride. Expert 
Rev Ophthalmol. 2009;4(1):59–64.
  104.  van der Bijl P, van Eyk A, Meyer D. Effects of three penetration 
enhancers on transcorneal permeation of cyclosporine. Cornea. 
2001;20(5):505–558.
  105.  Sengupta KK, Mikherji R. Essentials Ocular Pharmacology and 
Therapeutics. 1st ed. Kent, UK: Anshan Pub.; 2007.
  106.  Polizzi A, Siniscalchi C, Mastromarino A, Sacca S. Effect of vori-
conazole on a corneal abscess caused by fusarium. Acta Ophthalmol 
Scand. 2004;82(6):762–764.
  107.  Prats CH, Tello FL, Jose ABS, Otaolaurruchi JS, Baines JPO. 
Voriconazole in fungal keratitis caused by Scedosporium apiosper-
mum. Ann Pharmacother. 2004;38(3):414–417.
  108.  Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, 
Althmaus C. Successful treatment of ocular invasive mould infec-
tion (fusariosis) with the new antifungal agent voriconazole. Br J 
Ophthalmol. 2000;84(8):932–933.
  109.  Jones A, Muhtaseb M. Use of voriconazole in fungal keratitis.   
J Cataract Refract Surg. 2008;34(2):183–184.Clinical Ophthalmology 2010:4
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
405
Voriconazole eye drops in fungal keratitis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  110.  Al-Badriyeh D, Leung L, Davies GE, Stewart K, Kong D. Successful 
salvage treatment of Scedosporium apiospermum keratitis with 
topical voriconazole after failure of vatamycin. Ann Pharmacother. 
2009;43(6):1139–1142.
  111.  Al-Badriyeh D, Leung L, Davies GE, Stewart K, Kong D. Suc-
cessful use of topical voriconazole 1% alone as first-line antifungal 
therapy against Candida albicans keratitis. Ann Pharmacother. 
2009;43(12):2103–2107.
  112.  Al-Badriyeh D, Li J, Stewart K, et al. Stability of extemporaneously 
prepared voriconazole ophthalmic solution. Am J Health Syst Pharm. 
2009;66(16):1478–1483.
  113.  Lau D, Leung L, Fedinands M, et al. Penetration of 1% voriconazole 
eye drops into human vitreous humour – a prospective, open-label 
study. Clin Experiment Ophthalmol. 2009;37(2):197–200.